Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2015

Open Access 01-12-2015 | Research

Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients

Authors: Juntana Pattanaphesaj, Montarat Thavorncharoensap

Published in: Health and Quality of Life Outcomes | Issue 1/2015

Login to get access

Abstract

Background

The EQ-5D is a health-related quality of life instrument which provides a simple descriptive health profile and a single index value for health status. The latest version, the EQ-5D-5L, has been translated into more than one hundred languages worldwide - including Thai. This study aims to assess the measurement properties of the Thai version of the EQ-5D-5L (the 5L) compared to the EQ-5D-3L (the 3L).

Methods

A total of 117 diabetes patients treated with insulin completed a questionnaire including the 3L and the 5L. The 3L and 5L were compared in terms of distribution, ceiling, convergent validity, discriminative power, test-retest reliability, feasibility, and patient preference. Convergent validity was tested by assessing the relationship between each dimension of the EQ-5D and SF-36v2 using Spearman’s rank-order correlation. Discriminative power was determined by the Shannon index (H ′) and Shannon’s Evenness index (J ′). The test-retest reliability was assessed by examining the intraclass correlation coefficient (ICC) and Cohen’s weighted kappa coefficient.

Results

No inconsistent response was found. The 5L trended towards a slightly lower ceiling compared with the 3L (33% versus 29%). Regarding redistribution, 69% to 100% of the patients answering level 2 with the 3L version redistributed their responses to level 2 with the 5L version while about 9% to 22% redistributed their responses to level 3 with the 5L version. The Shannon index (H ′) improved with the 5L while the Shannon's Evenness index (J ′) reduced slightly. Convergent validity and test-retest reliability was confirmed for both 3L and 5L.

Conclusions

Evidence supported the convergent validity and test-retest reliability of both the 3L and 5L in diabetes patients. However, the 5L is more promising compared to the 3L in terms of a lower ceiling, more discriminatory power, and higher preference by the respondents. Thus, the 5L should be recommended as a preferred health-related quality of life measure in Thailand.
Literature
1.
Williams A. The EuroQol instrument. In: KIND P, BROOKS R, RABIN R, editors. EQ-5D concepts and methods: a developmental history. Dordrecht: Springer; 2005. p. 1–17.CrossRef
2.
Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–43.CrossRefPubMed
3.
4.
Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253–8.CrossRefPubMed
5.
Sakthong P. Measurement of clinical-effect: utility. J Med Assoc Thai. 2008;91 Suppl 2:S43–52.PubMed
6.
7.
Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res. 1993;2:169–80.CrossRefPubMed
8.
Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an adult US sample. Qual Life Res. 1998;7:155–66.CrossRefPubMed
9.
Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736–49.CrossRefPubMed
10.
Badia X, Schiaffino A, Alonso J, Herdman M. Using the EuroQoI 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res. 1998;7:311–22.CrossRefPubMed
11.
Kaarlola A, Pettila V, Kekki P. Performance of two measures of general health-related quality of life, the EQ-5D and the RAND-36 among critically ill patients. Intensive Care Med. 2004;30:2245–52.CrossRefPubMed
12.
Houle C, Berthelot J-M. A Head-to-Head Comparison of the Health Utilities Mark 3 and the EQ-5D for the Population Living in Private Households in Canada. Qual Life Newsletter. 2000;24:5–6.
13.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRefPubMedCentralPubMed
14.
Oemar M, Janssen B. EQ-5D-5L user guide. Rotterdam: EuroQol Group; 2013.
15.
Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level system with a five-level version. Value Health. 2008;11:275–84.CrossRefPubMed
16.
Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care. 2007;45:259–63.CrossRefPubMed
17.
18.
Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22:1717–27.CrossRefPubMedCentralPubMed
19.
Craig BM, Pickard AS, Lubetkin EI. Health problems are more common, but less severe when measured using newer EQ-5D versions. J Clin Epidemiol. 2014;67:93–9.CrossRefPubMedCentralPubMed
20.
Scalone L, Ciampichini R, Fagiuoli S, Gardini I, Fusco F, Gaeta L, et al. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Qual Life Res. 2013;22:1707–16.CrossRefPubMed
21.
Kim SH, Kim HJ, Lee SI, Jo MW. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Qual Life Res. 2012;21:1065–73.CrossRefPubMed
22.
Tran BX, Ohinmaa A, Nguyen LT. Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients. Health Qual Life Outcomes. 2012;10:132.CrossRefPubMedCentralPubMed
23.
Kim TH, Jo MW, Lee SI, Kim SH, Chung SM. Psychometric properties of the EQ-5D-5L in the general population of South Korea. Qual Life Res. 2013;22:2245–53.CrossRefPubMed
24.
Jia YX, Cui FQ, Li L, Zhang DL, Zhang GM, Wang FZ, et al. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual Life Res. 2014;23:2355–63.CrossRefPubMed
25.
Cabasés JM, Errea M, Hernández-Arenaz I. Comparing the psychometric properties of the EQ-5D-5L between mental and somatic chronic patients populations. Spain: Department of Economics, Public University of Navarra; 2013.
26.
van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708–15.CrossRefPubMed
27.
Tongsiri S, Cairns J. Estimating population-based values for EQ-5D health states in Thailand. Value Health. 2011;14:1142–5.CrossRefPubMed
28.
Kimman M, Vathesatogkit P, Woodward M, Tai ES, Thumboo J, Yamwong S, et al. Validity of the Thai EQ-5D in an occupational population in Thailand. Qual Life Res. 2013;22:1499–506.CrossRefPubMed
29.
Leurmarnkul W, Meetam P. Properties testing of the retranslated SF-36 (Thai version). Thai J Pharm Sci. 2005;29:69–88.
30.
Lim LL, Seubsman SA, Sleigh A. Thai SF-36 health survey: tests of data quality, scaling assumptions, reliability and validity in healthy men and women. Health Qual Life Outcomes. 2008;6:52.CrossRefPubMedCentralPubMed
31.
Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed
32.
Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new quality of life instrument. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven Publishers; 1995. p. 49–56.
33.
Bas Janssen MF, Birnie E, Bonsel GJ. Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon’s indices. Qual Life Res. 2007;16:895–904.CrossRefPubMed
34.
Fleiss JL, Levin B, Paik MC. The measurement of interrater agreement. In: Statistical methods for rates and proportions. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2004.
35.
Laver-Fawcett A. Principles of assessment and outcome measurement for occupational therapists and physiotherapists: theory, skills and application. London: John Wiley and Sons Ltd.; 2007.
36.
Kottner J, Audige L, Brorson S, Donner A, Gajewski BJ, Hrobjartsson A, et al. Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed. J Clin Epidemiol. 2011;64:96–106.CrossRefPubMed
37.
38.
Jacobson AM, Groot MD, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care. 1994;17:267–74.CrossRefPubMed
39.
Bundhamcharoen K, Odton P, Phulkerd S, Tangcharoensathien V. Burden of disease in Thailand: changes in health gap between 1999 and 2004. BMC Public Health. 2011;11:53.CrossRefPubMedCentralPubMed
40.
Sakthong P, Charoenvisuthiwongs R, Shabunthom R. A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type 2 diabetes. Health Qual Life Outcomes. 2008;6:71.CrossRefPubMedCentralPubMed
Metadata
Title
Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients
Authors
Juntana Pattanaphesaj
Montarat Thavorncharoensap
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2015
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-014-0203-3

Other articles of this Issue 1/2015

Health and Quality of Life Outcomes 1/2015 Go to the issue

Research

Assessment of health-related quality of life using the SF-36 in Chinese cervical spondylotic myelopathy patients after surgery and its consistency with neurological function assessment: a cohort study

Research

Validation of the Dutch Aging Perceptions Questionnaire and development of a short version

Research

Development and psychometric testing of a barriers to HIV testing scale among individuals with HIV infection in Sweden; The Barriers to HIV testing scale-Karolinska version

Research

Health-related quality of life in people with type 1 Diabetes Mellitus: data from the Brazilian Type 1 Diabetes Study Group

Short report

Confirmatory factor analysis of the Korean version of the short-form McGill pain questionnaire with chronic pain patients: a comparison of alternative models

Research

Translation, cross-cultural adaptation and psychometric evaluation of yoruba version of the short-form 36 health survey